Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Novartis to shut Ontario plant next year, Globe and Mail reports
Yahoo/Fly on the Wall
Friday, December 13, 2013 - 8:34am
tags:
Ontario, Novartis, drug manufacturing
The Weight Loss Drug Company Investors Need to Watch Out For
Motley Fool
Friday, December 13, 2013 - 8:32am
tags:
beloranib, Zafgen, Vivus, Arena Pharmaceuticals
Is BIND Therapeutics Ready To Fly Higher?
Seeking Alpha
Friday, December 13, 2013 - 8:28am
tags:
Bind Therapeutics, OncoMed
2013's Untold Biotech Story: Success Of The 2011-12 IPO Class
Forbes
Thursday, December 12, 2013 - 7:33pm
tags:
IPOs, biotech
FDA panel backs Bristol diabetes drug after prior rejection
Yahoo/Reuters
Thursday, December 12, 2013 - 5:01pm
tags:
FDA, advisory panels, Bristol-Myers Squibb, diabetes, Dapagliflozin
FDA panel throws dirt on Bristol-Myers' orphan drug metreleptin
Fierce Biotech
Thursday, December 12, 2013 - 4:15pm
tags:
FDA, advisory panels, Bristol-Myers Squibb, metreleptin, AstraZeneca, partial lipodystrophy
Kindred, TetraLogic stretch for $100M-plus as the biotech IPO market simmers
Fierce Biotech
Thursday, December 12, 2013 - 11:54am
tags:
Kindred, TetraLogic, IPOs
Merck's new allergy pill faces stubborn skepticism on the eve of its FDA review
Fierce Biotech
Thursday, December 12, 2013 - 11:49am
tags:
Merck, Grastek, allergic rhinitis
Avinger draws new financing to back testing of light-enhanced PAD catheter
Fierce Medical Devices
Thursday, December 12, 2013 - 11:45am
tags:
peripheral artery disease, PDL Biopharma, PAD catheter, devices, Avinger
Drugmakers, beware of tweets that trigger stock moves
Fierce Pharma
Thursday, December 12, 2013 - 11:44am
tags:
twitter, social media, Medivir
Think fast: A new cognition study could add $350M to Lundbeck's Brintellix sales
Fierce Pharma
Thursday, December 12, 2013 - 11:24am
tags:
Lundbeck, Brintellix, antidepressants
Attorneys General Want FDA To Rescind Painkiller Approval
Pharmalot
Thursday, December 12, 2013 - 11:18am
tags:
FDA, painkillers, Zohydro ER, Zogenix
Avastin Misses Mark Again in Breast Cancer
MedPage Today
Thursday, December 12, 2013 - 11:15am
tags:
Avastin, Roche, HER-2 postive breast cancer
Roche in deal worth up to $600 mln for Prothena Parkinson's drug
Yahoo/Reuters
Thursday, December 12, 2013 - 11:13am
tags:
Roche, Prothena, Parkinson's Disease, PRX-022
Keep an Eye on AstraZeneca, Avanir, Bristol-Myers Squibb and VIVUS Today
Motley Fool
Thursday, December 12, 2013 - 11:12am
tags:
AstraZeneca, Avair, Bristol-Myers Squibb, Vivus, metreleptin, Nuedexta, Avanafil, Sanofi
Corcept files IND with FDA for Phase I oncology study
The Fly on the Wall
Thursday, December 12, 2013 - 11:04am
tags:
Corcept Therapeutics, FDA, mifepristone, triple-negative breast cancer
FDA panel backs use of Boston Scientific anti-stroke device
Reuters
Thursday, December 12, 2013 - 8:44am
tags:
FDA, devices, Boston Scientific, WATCHMAN, stroke, advisory panels
3 Important Catalysts That Fueled Repligen in 2013
Motley Fool
Thursday, December 12, 2013 - 8:42am
tags:
Repligen, Orencia, Bristol-Myers Squibb, monoclonal antibodies
Synta Pharmaceuticals announces interim results from ENCHANT-1 Ganetespib trial
Yahoo/Fly on the Wall
Thursday, December 12, 2013 - 8:38am
tags:
Synta Pharmaceuticals, ganetespib, metastatic breast cancer
FDA approves 6 low-cost versions of blockbuster antidepressant pill Cymbalta
Yahoo/AP
Thursday, December 12, 2013 - 7:16am
tags:
FDA, patents, antidepressants, Cymbalta, Eli Lilly

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.